Non-linear Pharmacokinetics of MDMA ( “ Ecstasy ” ) and its Major Metabolites in Squirrel Monkeys at Plasma Concentrations of MDMA that Develop After Typical Psychoactive Doses

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Accumulation of Neurotoxic Thioether Metabolites of 3,4-(±)-Methylenedioxymethamphetamine in Rat Brain

  2008cited by this paper
• Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.

  2007cited by this paper
• Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA

  2006cited by this paper
• A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers

  2006cited by this paper
• Pharmacokinetic Profile of Single and Repeated Oral Doses of MDMA in Squirrel Monkeys: Relationship to Lasting Effects on Brain Serotonin Neurons

  2006cited by this paper
• Contribution of Cytochrome P450 2D6 to 3,4-Methylenedioxymethamphetamine Disposition in Humans

  2005cited by this paper
• The Role of Metabolism in 3,4-(±)-Methylenedioxyamphetamine and 3,4-(±)-Methylenedioxymethamphetamine (Ecstasy) toxicity

  2004cited by this paper
• The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)

  2003cited by this paper
• Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.

  2002influential reference
• Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans.

  2001cited by this paper
• Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs.

  2000influential reference
• Debrisoquine hydroxylase (CYP2D6) and prostate cancer.

  1998cited by this paper
• Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion.

  1996influential reference
• Interspecies scaling: a comparative study for the prediction of clearance and volume using two or more than two species.

  1996cited by this paper
• Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS.

  1996cited by this paper

• Dose concentration and spatial memory and brain mitochondrial function association after 3,4-methylenedioxymethamphetamine (MDMA) administration in rats

  2020cites this paper
• Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

  2018cites this paper
• Nonlinear Pharmacokinetics of (±)3,4-Methylenedioxymethamphetamine (MDMA) and Its Pharmacodynamic Consequences in the Rat

  2014cites this paper
• Effect of 3,4-methylenedioxymethamphetamine on the toxicokinetics and sedative effects of the drug of abuse, γ-hydroxybutyric acid.

  2014cites this paper
• Nonlinear Pharmacokinetics of ( 6 )3, 4-Methylenedioxymethamphetamine (MDMA) and Its Pharmacodynamic Consequences in the Rat

  2013cites this paper
• Studies of (±)-3,4-Methylenedioxymethamphetamine (MDMA) Metabolism and Disposition in Rats and Mice: Relationship to Neuroprotection and Neurotoxicity Profile

  2013cites this paper
• Behavioral Effects and Pharmacokinetics of (±)-3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) after Intragastric Administration to Baboons

  2013cites this paper
• Effects of Repeated 3,4-Methylenedioxymethamphetamine Administration on Neurotransmitter Efflux and Sensory-Evoked Discharge in the Ventral Posterior Medial Thalamus

  2012cites this paper
• Pharmacodynamic interactions between MDMA and concomitants in MDMA tablets on extracellular dopamine and serotonin in the rat brain.

  2011cites this paper
• (±)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice.

  2011influential citation
• Metabolism and Disposition of 3,4-Methylenedioxymethamphetamine (“Ecstasy”) in Baboons after Oral Administration: Comparison with Humans Reveals Marked Differences

  2011cites this paper
• Nonlinear Pharmacokinetics of 5-Methoxy-N,N-dimethyltryptamine in Mice

  2011cites this paper
• Nonlinear Pharmacokinetics of 5-Methoxy- N,N -dimethyltryptamine in Mice

  2011cites this paper
• Endocrine and Neurochemical Effects of 3,4-Methylenedioxymethamphetamine and Its Stereoisomers in Rhesus Monkeys

  2010cites this paper
• Mice Lacking Multidrug Resistance Protein 1a Show Altered Dopaminergic Responses to Methylenedioxymethamphetamine (MDMA) in Striatum

  2010cites this paper
• Title page: Endocrine and neurochemical effects of MDMA and its stereoisomers in rhesus monkeys

  2010cites this paper
• Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine and Its Enantiomers in Mice: Pharmacokinetic Considerations

  2009cites this paper
• Effects of Dose and Route of Administration on Pharmacokinetics of (±)-3,4-Methylenedioxymethamphetamine in the Rat

  2009influential citation
• Molecular and Cellular Mechanisms of Ecstasy-Induced Neurotoxicity: An Overview

  2009cites this paper
• Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA).

  2009cites this paper
• Enantiomers of Methylenedioxy Designer Drugs The Role of Cytochrome P 450 s and Catechol-O-methyltransferase in Their Metabolism

  2009cites this paper